Hyaluronic acid versus placebo injection on POD1 following ACL reconstruction

Study Type: Therapy
OE Level of Evidence: N/A
Journal Level of Evidence: 1
60 patients scheduled for arthroscopic ACL reconstruction were randomized to receive an injection of either hyaluronic acid or placebo on the first day following the procedure. The purpose of this study was to compare measures of pain, function, and health-related quality of life between groups over a 12-month follow-up to determine if the use of hyaluronic acid can provide benefits in this patient population. The results demonstrated Please login to view the rest of this report. Please login to view the rest of this report.
Funding: Industry funded
Sponsor: Multiple industry funders
Conflicts: Consultant
Why was this study needed now?
Viscosupplementation using hyaluronic acid injections was developed for the management of mild to moderate knee osteoarthritis. This treatment has been demonstrated to provide pain and symptom relief in this patient population. Recently, interest in its use has been extended to the postoperative management following arthroscopic knee procedures, due to its theoretical effect in promoting joint hemostasis and reducing inflammation. This study sought to examine the effects of a hyaluronic acid injection on pain and function following anterior cruciate ligament (ACL) reconstruction.
What was the principal research question?
Does a single hyaluronic acid injection following ACL reconstruction have a significant effect on pain and function compared to a placebo injection when compared over a 12-month follow-up?
Population: 60 patients, 18 to 50 years of age, with a tear of the anterior cruciate ligament who were undergoing arthroscopic reconstruction were included. All procedures were performed with a semitendinosus and gracilis autograft.
Intervention: HA group: On the first postoperative day patients were administered an injection of hyaluronic acid alkyl derivative (HYADD)-4 24mg (n=30) (Mean age: 30.2+/-8.3)
Comparison: Placebo group: On the first postoperative day patients were administered an injection of 3mL of placebo (n=30) (Mean age: 30.8+/-10.6)
Outcomes: The outcome measures included: the Short Form 36-Item General Health Survey, the International Knee Documentation Committee (IKDC) subjective score, a visual analog scale for pain, a visual analog scale for general health status, the Tegner score, active and passive knee range of motion, knee swelling via knee circumference, and patient satisfaction. Adverse events were also recorded.
Methods: RCT
Time: Patients were assessed at 2 weeks, 1, 2, 6, and 12 months postoperatively
What were the important findings?
What should I remember most?
How will this affect the care of my patients?
The authors responsible for this critical appraisal and ACE Report indicate no potential conflicts of interest relating to the content in the original publication.